News

GSK's blood cancer drug gets EU approval
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
GSK's blood cancer drug fails to secure US FDA advisers' support
The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...
GSK wins EU approval for drug combos containing blood cancer drug Blenrep
GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...
GSK blood cancer drug fails to win backing of key US regulatory panel
GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its ...
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...
GSK Sales, Core Earnings Expected to Edge Lower -- Earnings Preview
SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...